Healios KK: Financial results for the 1st quarter of 2024
Healios KK: Notice regarding the recording of financial income and financial expenses
Healios KK: Joint Research Agreement with AND medical to Utilize Healios Technology and Culture Supernatant
Healios KK: Announcement of the conclusion of a joint research agreement with AND Medical to utilize culture supernatants
Healios KK: Healios Acquires Substantially All of the Assets of Athersys, Inc. Free and Clear of Liabilities, Becomes Sole Owner of MultiStem
Healios KK: Acquisition of all substantial assets of Assassis' - acquisition of sole rights to the somatic stem cell regenerative medicine product MultiStem Cell
Healios KK: Announcement of the presentation of research results on enK cell hepatocellular carcinoma at the 23rd Annual Meeting of the Japanese Society for Regenerative Medicine
Healios KK: Matters relating to business plans and growth potential
Healios KK: Presentation of the research results of Healios’ eNK cells on mesothelioma at AACR Annual Meeting 2024
Healios KK: Announcement of research results for enK cell mesothelioma at the American Cancer Society Annual Meeting (AACR Annual Meeting 2024)
Helios: Notice Concerning Reduction of Capital and Capital Reserve Funds and Appropriation of Surplus Funds
Helios: Notice regarding nomination of candidates for directors of Helios Co., Ltd.
Helios: Notice Concerning Decrease in Capital and Capital Reserve Amounts and Disposal of Surplus Funds
Helios: Notice regarding personnel affairs of directors
Helios: Announcement of the presentation of research results for enK (R) cell mesothelioma at the 23rd Annual Meeting of the Japanese Society for Regenerative Medicine
Healios KK: Stock Transfer Report Affirmations Related to Third-Party Allocation (New Shares)
Healios KK: Stock Transfer Report Affirmations Related to Third-Party Allocation (New Shares)
Healios KK: Stock Transfer Report Affirmations Related to Third-Party Allocation (New Shares)
Healios KK: FY2023 Financial Results (Material)
Healios KK: Notice regarding the recording of financial income and financial expenses (consolidated accounts) and the recording of non-operating income, non-operating expenses, special profits, and extraordinary losses (individual accounts)
No Data